Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosswog

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Neoplasia (New York, N.Y.)|November 2, 2017
Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk AssessmentCarolina Rosswog, Rene Schmidt, André Oberthuer, et al.
Oncoimmunology|April 8, 2026
Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatmentStefanie Höppner, Lisa Werr, Beata Szilagyi, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Nature Genetics|November 16, 2021
Chromothripsis followed by circular recombination drives oncogene amplification in human cancerCarolina Rosswog, Christoph Bartenhagen, Anne Welte, et al.
Cancer Research Communications|January 6, 2025
Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with NeuroblastomaJan F Hollander, Annabell Szymansky, Jasmin Wünschel, et al.
Klinische Padiatrie|May 9, 2025
GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025Thorsten Simon, Theresa Thole, Sveva Castelli, et al.
British Journal of Cancer|February 22, 2023
Genomic ALK alterations in primary and relapsed neuroblastomaCarolina Rosswog, Jana Fassunke, Angela Ernst, et al.
Nature Communications|November 17, 2020
Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastomaKonstantin Helmsauer, Maria E Valieva, Salaheddine Ali, et al.
Nature Communications|February 25, 2021
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteomeSabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastomaSveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Neoplasia (New York, N.Y.)|November 2, 2017
Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk AssessmentCarolina Rosswog, Rene Schmidt, André Oberthuer, et al.
Oncoimmunology|April 8, 2026
Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatmentStefanie Höppner, Lisa Werr, Beata Szilagyi, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Nature Genetics|November 16, 2021
Chromothripsis followed by circular recombination drives oncogene amplification in human cancerCarolina Rosswog, Christoph Bartenhagen, Anne Welte, et al.
Cancer Research Communications|January 6, 2025
Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with NeuroblastomaJan F Hollander, Annabell Szymansky, Jasmin Wünschel, et al.
Klinische Padiatrie|May 9, 2025
GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025Thorsten Simon, Theresa Thole, Sveva Castelli, et al.
British Journal of Cancer|February 22, 2023
Genomic ALK alterations in primary and relapsed neuroblastomaCarolina Rosswog, Jana Fassunke, Angela Ernst, et al.
Nature Communications|November 17, 2020
Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastomaKonstantin Helmsauer, Maria E Valieva, Salaheddine Ali, et al.
Nature Communications|February 25, 2021
Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteomeSabine A Hartlieb, Lina Sieverling, Michal Nadler-Holly, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2026
Current treatment strategies for first relapse of high-risk neuroblastomaSveva Castelli, Franziska Schulze, Theresa M Thole-Kliesch, et al.
Pageof 4